Zevra Therapeutics (NASDAQ:ZVRA) SVP Timothy Sangiovanni Sells 3,000 Shares

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) SVP Timothy Sangiovanni sold 3,000 shares of the stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $9.18, for a total transaction of $27,540.00. Following the completion of the transaction, the senior vice president directly owned 29,590 shares of the company’s stock, valued at approximately $271,636.20. The trade was a 9.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Zevra Therapeutics Trading Up 0.9%

NASDAQ ZVRA opened at $9.02 on Thursday. The stock has a market cap of $507.77 million, a P/E ratio of 18.91 and a beta of 0.99. The stock’s fifty day moving average price is $8.68 and its 200-day moving average price is $9.40. Zevra Therapeutics, Inc. has a 12 month low of $6.19 and a 12 month high of $13.16. The company has a current ratio of 8.62, a quick ratio of 8.57 and a debt-to-equity ratio of 0.46.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%.The business had revenue of $26.06 million during the quarter, compared to analyst estimates of $26.64 million. As a group, equities analysts forecast that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Zevra Therapeutics

Large investors have recently added to or reduced their stakes in the company. CWM LLC grew its holdings in Zevra Therapeutics by 399.5% in the third quarter. CWM LLC now owns 2,872 shares of the company’s stock worth $27,000 after purchasing an additional 2,297 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in Zevra Therapeutics by 30.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after buying an additional 1,280 shares during the last quarter. Russell Investments Group Ltd. increased its position in Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after buying an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after acquiring an additional 8,552 shares in the last quarter. Finally, Creative Planning purchased a new stake in shares of Zevra Therapeutics during the second quarter worth about $92,000. 35.03% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on ZVRA shares. Cantor Fitzgerald lowered their target price on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Canaccord Genuity Group lowered their price objective on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (d+)” rating on shares of Zevra Therapeutics in a report on Friday, January 9th. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, HC Wainwright set a $26.00 price target on Zevra Therapeutics in a research report on Tuesday, December 30th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.80.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.